Prestige Consumer Healthcare Inc. reported revenue of USD 283.4 million for the third quarter (Q3) of fiscal 2026, exceeding its outlook. Diluted earnings per share $(EPS)$ for Q3 were USD 0.97, while adjusted diluted EPS stood at USD 1.14. For the nine months ended December 31, 2025, the company reported year-to-date revenue in line with its narrowed fiscal 2026 outlook of approximately USD 1.1 billion, with an anticipated organic revenue decline of about 3 percent for the year. Adjusted diluted EPS for fiscal 2026 is expected to be approximately USD 4.54, with free cash flow projected at USD 245 million or more. During the quarter, Prestige Consumer Healthcare Inc. repurchased approximately 0.8 million shares. The company also announced the successful completion of its acquisition of eye care supplier Pillar5 Pharma, Inc. in December. Management highlighted the benefits of its diverse business model and strong financial profile, noting that these contributed to exceeding revenue expectations and delivering solid profitability in Q3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Consumer Healthcare Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649543-en) on February 05, 2026, and is solely responsible for the information contained therein.